

Jason R Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/168211/publications.pdf>

Version: 2024-02-01

37
papers

582
citations

759233

12
h-index

642732

23
g-index

37
all docs

37
docs citations

37
times ranked

487
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained, complete response to pexidartinib in a patient with <i>CSF1R</i> -mutated Erdheim-Chester disease. <i>American Journal of Hematology</i> , 2022, 97, 293-302.	4.1	9
2	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. <i>Oncologist</i> , 2022, 27, 144-148.	3.7	3
3	International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. <i>Blood</i> , 2022, 139, 2601-2621.	1.4	63
4	Multimodality imaging of cardiac involvement in Erdheim-Chester disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, , .	1.2	0
5	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	17.0	17
6	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	6.2	1
7	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	3
8	Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19532-e19532.	1.6	0
9	Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	7
10	How We Do It: A Multidisciplinary Approach to ¹⁷⁷ Lu DOTATATE Peptide Receptor Radionuclide Therapy. <i>Radiology</i> , 2021, 298, 261-274.	7.3	21
11	Testicular ¹⁸ F-FDG PET/CT uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021, 96, E81-E83.	4.1	3
12	Single-agent cladribine as an effective frontline therapy for adults with Langerhans cell histiocytosis. <i>American Journal of Hematology</i> , 2021, 96, E146-E150.	4.1	21
13	¹⁸ F-FDG PET/CT of hepatocellular adenoma subtypes and review of literature. <i>Abdominal Radiology</i> , 2021, 46, 2604-2609.	2.1	3
14	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7049-7049.	1.6	0
15	<i>BRAF</i> ^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7050-7050.	1.6	0
16	Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis. <i>American Journal of Hematology</i> , 2021, 96, E298-E301.	4.1	7
17	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. <i>American Journal of Hematology</i> , 2021, 96, 1604-1610.	4.1	18
18	Frequency and Characteristics of Nodal and Deltoid FDG and ¹¹ C-Choline Uptake on PET Performed After COVID-19 Vaccination. <i>American Journal of Roentgenology</i> , 2021, 217, 1206-1216.	2.2	30

#	ARTICLE	IF	CITATIONS
19	The association of incidental positron emission tomography uptake in the esophagus to gastroesophageal reflux disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
20	Efficacy of Cobimetinib in Rosai-Dorfman Disease. <i>Blood</i> , 2021, 138, 1506-1506.	1.4	1
21	Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity. <i>Blood</i> , 2021, 138, 2518-2518.	1.4	3
22	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. <i>Blood</i> , 2021, 138, 2566-2566.	1.4	0
23	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	1.4	0
24	Safety and Efficacy of Percutaneous Image-Guided Mediastinal Mass Core-Needle Biopsy. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 1100-1108.	2.4	4
25	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	3.5	105
26	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	1.3	9
27	Computed tomographically guided transthoracic biopsy of a cardiac mass in the right ventricular outflow tract. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, e115-e118.	0.8	2
28	Unusual manifestations of diffuse-type tenosynovial giant cell tumor in two patients: importance of radiologic-pathologic correlation. <i>Skeletal Radiology</i> , 2020, 49, 483-489.	2.0	10
29	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF</i> ^{V600E} -Mutated Adult Langerhans Cell Histiocytosis. <i>Oncologist</i> , 2020, 25, 1001-1004.	3.7	25
30	Low-dose vemurafenib monotherapy in <i>BRAF</i> ^{V600E} -mutated Erdheim-Chester disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 2733-2737.	1.3	9
31	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	1.3	14
32	Thoracic positron emission tomography: F-fluorodeoxyglucose and beyond. <i>Journal of Thoracic Disease</i> , 2020, 12, 6978-6991.	1.4	0
33	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2054-2071.	3.0	116
34	Radiolocalization of atypical lesions for intraoperative identification: technical factors, localization quality, success rates, patient safety, and spectrum of applications. <i>World Journal of Surgical Oncology</i> , 2019, 17, 88.	1.9	1
35	Skeletal Metastasis Evaluation. <i>PET Clinics</i> , 2019, 14, 103-120.	3.0	9
36	Rheumatoid pulmonary nodules: clinical and imaging features compared with malignancy. <i>European Radiology</i> , 2019, 29, 1684-1692.	4.5	22

#	ARTICLE	IF	CITATIONS
37	¹⁸ F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. Journal of Nuclear Medicine, 2018, 59, 774-779.	5.0	46